Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Cancer Immunology, Immunotherapy : CII|November 11, 2018
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinomaCharlotte M Huijts, Inge M Werter, Sinéad M Lougheed, et al.
Cancer Immunology, Immunotherapy : CII|October 27, 2016
High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA statusJohn P Veluchamy, A Marijne Heeren, Jan Spanholtz, et al.
BMC Cancer|October 13, 2010
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatmentNikol Snoeren, Emile E Voest, Andre M Bergman, et al.
JAMA Network Open|September 10, 2021
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal CancerSietske C van Nassau, Marinde J Bond, Ilva Scheerman, et al.
Proteomics. Clinical Applications|February 16, 2019
Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib MalateAlice C O'Farrell, Ian S Miller, Rhys Evans, et al.
Neoplasia (New York, N.Y.)|January 16, 2017
Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA studyNikol Snoeren, Richard van Hillegersberg, Sander B Schouten, et al.
Cancer Research|October 3, 2013
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinomaAmir Avan, Viola Caretti, Niccola Funel, et al.
Journal of Proteomics|February 13, 2018
Exploration of the platelet proteome in patients with early-stage cancerSiamack Sabrkhany, Marijke J E Kuijpers, Jaco C Knol, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2019
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimusInge M Werter, Charlotte M Huijts, Sinéad M Lougheed, et al.
Oral Oncology|June 26, 2020
Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancerDennis Poel, François Rustenburg, Daoud Sie, et al.
Pageof 5